Hydrophilic and lipophilic metabolites were studied through GC-MS (Gas Chromatography-23
Mass Spectrometry) platform, followed by multivariate statistic protocols. 
METHODS

27
1.Population 28
The protocol of the study was approved by the Ethical Committee of the Sacco Hospital (Milan) 29
and all women signed a written informed consent. Only singleton spontaneous pregnancies, 30 with maternal age between 18 and 40 years and of Caucasian ethnicity were included in the 31 study. Exclusion criteria were maternal preexisting diseases, fetal and maternal infections, 32 alcohol or drugs abuse, fetal malformations or chromosomal disorders, BMI< 18. 5 Obese patients were given specific nutritional advice and recommendations on weight gain in 6 pregnancy. Eight obese women had a diagnosis of Gestational Diabetes Mellitus (GDM) 7
[OB/GDM(+)] based on an Oral Glucose Tolerance Test (OGTT, 75 g), according to FIGO 8 guidelines [25] . OB/GDM(+) were constantly checked for glycaemia and were given lifestyle 9 and dietary indications for glycemic control. None of the studied women needed insulin 10
therapy. 11
Maternal medical history, demographic, anthropometric, and obstetric data, as well as neonatal 12 outcome data were recorded at recruitment and after delivery. Maternal gestational weight gain 13 (GWG) was recorded. 14 15
2.Sample Collection 16
Placentas from elective caesarean section were measured recording placental weight, area and 17 thickness as previously described [5] . Placental tissue was collected from a not-impaired part 18 of the placental disc, after discarding the maternal decidua layer, washed in PBS, then cut into 19 small pieces and immediately frozen in liquid nitrogen. The tissue was then transferred into 20 a -80°C freezer. Samples were sent to the University of Cagliari to be analyzed by the GC-MS 21
platform. 22 23
3.Sample Preparation 24
The extraction method was optimized from literature methods [17-18, 26-27]. A piece of 25 placental tissue of about 100 mg was rapidly weighed, put in a glass mortar on ice with 1.9 mL 26 of chloroform/methanol/water (1.4/1.4/1, 700/700/500 l) and homogenized with a Potter-27
Elvehjem homogenizer for 2 minutes. The mixture was kept at 4°C for 15 min, then centrifuged 28 at 14000 rpm for 10 min at 4°C. The upper (hydrophilic) and lower (lipophilic) phases were 29 separated: the hydrophilic was dried in a vacuum concentrator (Eppendorf Concentrator Plus) 30 overnight; the lipophilic in a glass vacuum desiccator under fume-hood for 2 h. The volume of 31 extraction solution was normalized to 100 mg of tissue, with 1000 L of the upper phase and 32 600 L of the lower being dried down for 100 mg of tissue [17]. The dried fractions were stored 1 at -80°C until analysis. added and left for 1 h at RT. Just before GC-MS analysis, samples were diluted with a hexane 7 solution (600 µL) of tetracosane (0.006 mg/mL) as internal standard, then analyzed using a 8 Agilent 5977B interfaced to the GC 7890B with a DB-5ms column (J & W) [injector 9 temperature at 230°C, detector temperature at 280°C, helium carrier gas flow rate of 1 mL/min]. 10
The GC oven temperature program was 90°C for 1 min, ramped by 10°C/min to 270°C with 7 11 min hold time. The sample (1 µL) was injected in split (1:10) mode. After a solvent delay of 3 12 min, mass spectra were acquired in full scan mode using 2.28 scans/s with a mass range of 50-13 700 Amu. 14 15
Lipophilic Phase 16
150 µL of chloroform:methanol (1:1) and 100 µL of 14% BF3 in methanol were added to each 17 vial, samples were vortex mixed and left for 90 min at 80ºC into an heating block. Once cooled, 18 600 µL hexane and 300 µL water were added, samples were vortex mixed and centrifuged for 19 2 min at 1400 rpm. The organic layer (upper) was transferred into glass vials and dried in a 20 vacuum concentrator. Samples were then reconstituted with 400 µL hexane and injected to be 21 analyzed with Agilent 5977B interfaced to the GC 7890B equipped with a DB-5ms column (J 22 & W) [injector temperature at 230°C, detector temperature at 280°C, helium carrier gas flow 23 rate of 1 mL/min]. The initial column temperature was 60ºC for 2 minutes, ramped by 15ºC/min 24 to 150ºC, and then by 4°C/min to 230ºC, hold for 20 min. The sample (1 µL) was injected in 25 split (1:10) mode. After a solvent delay of 4 min, mass spectra were acquired in full scan mode 26 using 2.28 scans/s with a mass range of 50-700 Amu. 27 28
4.Data Analysis 29
Each acquired chromatogram was analyzed with the free software AMDIS 30
[http://chemdata.nist.gov/mass-spc/amdis] using an in-house made library comprising 222 31 metabolites. Some metabolites were identified using NIST08 and the GMD [http://gmd.mpimp-32 golm.mpg.de/] the metabolite was considered positively identified with a match factor 70%.
hydrophilic phase analysis produced a matrix containing 78 metabolites: 55 accurately 1 identified, 1 unknown compound matching an equally unknown of GMD group, and 22 2 unknown molecules recurring in every sample. The lipophilic phase produced a matrix 3 containing 22 metabolites: 17 accurately identified compounds and 5 unknown molecules 4 recurring in every sample. The obtained data matrices were successively subjected to statistical 5 analysis. 6 7
5.Statistical Analysis 8
Sample size was adequate to assure the minimum precision requested for a pilot study [28]. 9
Clinical characteristics and data displayed a normal distribution (Kolmogorov-Smirnov Test), 10 and were thus compared between groups with parametric statistics (t-test). Correction to t-test 11 was applied when the equality of variances assumption was violated (Levene's test). 12 Differences were considered statistically significant when p ≤ 0.05. 13
Univariate analysis (ANOVA, ANalysis Of VAriance, and t-test) and multivariate models 14 based on Partial Least Square-Discriminant Analysis (PLS-DA) were performed in 15 for the evaluation of statistical parameters (correlation coefficient-R 2 , CV coefficient Q 2 ). This 21 allowed to determine the optimal number of components for the model description. The 22 permutation test was then applied to each model to investigate its predictive ability using the 23 prediction accuracy test to set a permutation number (n=100 and p < 0.01). 24
25
RESULTS
26
Characteristics of the Population
27
Maternal and delivery characteristics of the two study groups are reported in Table 1 . No 28 significant differences were observed in fetal and placental data at delivery between OB and 29 NW. Moreover we found no significant differences between OB/GDM(+) and OB/GDM(-) 30 except for maternal basal glycaemia (81.9 ± 7.0 vs 98.0 ± 7.9 mg/dL respectively, p ≤ 0.01) and 31 placental weight (466.4 ± 65.7 vs 561.1 ± 67.5 g respectively, p ≤ 0.01) [ Figure 1A ]. In obese 7 placentas higher levels of nucleobases (uracil, hypoxanthine and a not clearly identified purine 8 derivative), glucose-6-phosphate, 3-phoshoglycerate, glycerol, nicotinamide and the amino 9 acids tyrosine, isoleucine, phenylalanine, leucine and serine were found. On the other side lower 10 amounts of the amino acids lysine, taurine, aspartic acid and glutamine, along with the 11 nucleosides inosine and guanosine, an inositol isomer and gluconic acid were detected [ Figure  12 1B]. 13
14
DIFFERENCES IN RELATION TO GDM 15
We then explored the possible role of GDM in the hydrophilic metabolites profile of obese To our knowledge, this is the first study providing preliminary data on a broad range of 9 metabolites in obese placentas delivered by elective caesarean section, thus avoiding molecular 10 alterations due to labor. We applied metabolomics to investigate possible placental metabolic 11 differences that can be relevant in two extreme maternal groups of the BMI scale: obese and 12 normal weight. Of note, this study involved pregnant women with a well characterized clinical 13 condition, undergoing regular prenatal checks in a dedicated clinic, and provided with 14 nutritional and life style advice. This resulted in non-complicated maternal and fetal outcomes, 15 and normal birthweights. Nonetheless, important differences were observed in the placental 16 metabolites. These results may carefully be considered as potential markers for development of 17 adult diseases. This study shows preliminary data in a limited population sample size. 5
As such, the aim of this work was to identify metabolic perturbations in our samples of OB and 6 NW placentas. Thus, here we report preliminary results and no definitive conclusion can be 7 drawn from our data. However, this study provides interesting driving information for future 8 metabolic pathways analysis, with a larger sample size. 9
Obese pregnant women were carefully selected and matched to control pregnancies with similar 10 characteristics except for BMI. For this reason, these results cannot be extended to the general 11 obese population, since their favorable pregnancy outcomes were likely modulated by optimal 12 prenatal care in these women. 13
This study applied the same analytical platform (GC-MS) to both hydrophilic and lipophilic 14 phase. LC-MS instruments are the most used for lipid profiling studies, allowing for the 15 detection of a very large number of metabolites, covering all lipid classes. Nevertheless, the 16 easier identification of metabolites provided by GC-MS, allowed to get interesting information, 17
although not exhaustive, for this preliminary study. 18
Another potential limitation is that, due to the small amount of tissue available, no pool sample 19 was prepared. 20
21
Conclusions
Placental metabolome analysis of obese pregnancies suggested changes in metabolites' 23 concentrations associated with obesity, specifically higher glycerol levels, with a similar trend 24 for a number of fatty acids. Differences were also found for some amino acids and metabolites 25 involved in nucleotide production, antioxidant defenses and lipid synthesis, suggesting a 26 generalized shift towards higher placental metabolism. 27
This study can lay the foundation to further metabolomic placental characterization in the 28 context of obesity. This can represent an additional missing link combining the two separated 29 biological compartments of maternal blood and amniotic fluid, already investigated in other 30 studies [6,7,9,11]. 31
Moreover, future works based on these preliminary data will help identifying a specific 32 placental phenotype of obese pregnancies, even in the setting of optimal prenatal care and 33 pregnancy outcomes. These data are not unexpected and lead to two major conclusions: 1) the 1 need to optimize maternal BMI before conception and 2) the presence of specific metabolic 2 signatures that may reflect underlying changes in the intrauterine metabolic environment. 
